Sclafani Anthony P, Romo Thomas, Jacono Andrew A
Division of Facial Plastic Surgery, Department of Otolaryngology-Head and Neck Surgery, The New York Eye and Ear Infirmary, 310 E 14th St, North Building, Sixth Floor, New York, NY 10003, USA.
Arch Facial Plast Surg. 2002 Oct-Dec;4(4):252-7. doi: 10.1001/archfaci.4.4.252.
To evaluate the effects of Cymetra (micronized AlloDerm tissue) in rejuvenating the aging and atrophic lip.
Forty-four patients aged 32 to 80 years who reported age-related changes in the size and contour of the upper lip.
Patients were randomized to treatment with either Cymetra or glutaraldehyde cross-linked bovine collagen (Zyplast). Standardized photographs of each subject were taken before and after treatment initially and 3, 6, 9, and 12 months after initial treatment. Patients were monitored for signs of hypersensitivity, infection, and inflammation.
Digital photographs were analyzed for changes in the nasolabial angle, percentage of the total lip accounted for by the exposed red lip in the midline and on the lateral view, the visible red upper and lower lip surface areas, and the anterior projection of the upper and lower lips.
All patients tolerated treatment well without any significant local or systemic complications. Nineteen patients were treated with Cymetra and 25 with Zyplast. Cymetra-treated patients were more likely than Zyplast-treated patients at 12 months (3 months after the previous treatment) to have increased the percentage of red lip in the midline (84.6% vs 38.9%; P =.01), the vermilion height in the upper lip midline (84.6% vs 38.9%; P =.01), and the exposed red lower lip on the lateral view (69.2% vs 33.3%; P =.048) by at least 20%; increased the lower lip projection by 0.5 mm or more (69.2% vs 27.8%; P =.02); and decreased the nasolabial angle by at least 10 degrees (46.2% vs 16.7%; P =.07).
Cymetra is a suspension of particulate dermal matrix that seems to increase the upper lip bulk, vermilion, and lower lip projection after a threshold of Cymetra has been administered. There are few differences in any measured long-term (3 months after treatment) variables until the 12-month visit, when there were statistically significantly more Cymetra-treated patients with improved lip aesthetics than those treated with Zyplast. With repeated treatments, Cymetra seems to accumulate, producing a long-term effect superior to Zyplast in many patients.
评估Cymetra（微粉化同种异体真皮组织）对改善衰老和萎缩性唇部的效果。
44例年龄在32至80岁之间的患者，均有上唇大小和轮廓的年龄相关变化。
患者被随机分为接受Cymetra或戊二醛交联牛胶原蛋白（Zyplast）治疗。在治疗前、初始治疗后3、6、9和12个月对每位受试者拍摄标准化照片。对患者进行超敏反应、感染和炎症迹象的监测。
分析数码照片，观察鼻唇角、中线及侧位暴露红唇占全唇的百分比、可见红唇上下唇表面积以及上下唇的前突度的变化。
所有患者对治疗耐受性良好，未出现任何明显的局部或全身并发症。19例患者接受Cymetra治疗，25例接受Zyplast治疗。在12个月时（上次治疗后3个月），接受Cymetra治疗的患者比接受Zyplast治疗的患者更有可能使中线红唇百分比增加至少20%（84.6%对38.9%；P = 0.01）、上唇中线朱红色高度增加至少20%（84.6%对38.9%；P = 0.01）、侧位暴露的红唇下唇增加至少20%（分别为69.2%对33.3%；P = 0.048）；下唇前突增加0.5毫米或更多（69.2%对27.8%；P = 0.02）；鼻唇角减小至少10度（46.2%对16.7%；P = 0.07）。
Cymetra是一种颗粒状真皮基质悬液，在给予一定剂量后似乎能增加上唇体积、朱红色及下唇前突度。在12个月随访前，任何测量的长期（治疗后3个月）变量差异均较小，此时接受Cymetra治疗且唇部美学改善的患者在统计学上显著多于接受Zyplast治疗的患者。经反复治疗后，Cymetra似乎会蓄积，在许多患者中产生优于Zyplast的长期效果。
